Financial Performance - For the fiscal year ending December 31, 2025, product sales and commercialization rights revenue increased by 90% to RMB 574.1 million (USD 82.1 million) compared to RMB 980.7 million (USD 134.3 million) for the previous year[5][9]. - The company reported a net loss of RMB 1,243.0 million (USD 177.7 million), an increase of 206.4% from RMB 405.7 million (USD 55.6 million) in the previous year[11]. - Total revenue for the year ended December 31, 2025, was RMB 574,120 thousand, a decrease of 41.3% compared to RMB 980,650 thousand in 2024[75]. - Gross profit for 2025 was RMB 525,182 thousand, down from RMB 951,565 thousand in 2024, reflecting a gross margin decline[75]. - The company reported a basic and diluted loss per share of RMB 3.49 for 2025, compared to RMB 1.34 in 2024, indicating worsening profitability[75]. - The net cash outflow from operating activities was RMB 1,174.1 million for the year ending December 31, 2025, compared to RMB 111.4 million for the year ending December 31, 2024[128]. - The net cash inflow from financing activities was RMB 2,540.1 million for the year ending December 31, 2025, compared to RMB 314.8 million for the year ending December 31, 2024[129]. Research and Development - Research and development expenses increased by 20.1% to RMB 1,137.4 million (USD 162.7 million) from RMB 947.2 million (USD 129.8 million) in the previous year[10]. - The company is currently conducting nine ongoing Phase III clinical trials, with four approved by the FDA and EMA[5][7]. - The company has received IND approval for its proprietary BTK-targeted protein degrader APG-3288, preparing to initiate clinical studies for relapsed/refractory hematologic malignancies[15]. - The company is focusing on developing differentiated therapeutic candidates through its internal discovery capabilities, targeting traditionally undruggable proteins[55][56]. - The company is conducting global Phase III registration trials for Lisaftoclax in combination with AZA for frontline HR-MDS patients and with BTK inhibitors for previously treated CLL/SLL patients[160]. Product Sales and Market Expansion - Sales of Nairike® (Aorebatin) grew by 81% year-on-year to RMB 435.3 million (USD 62.2 million) from RMB 241.0 million (USD 33.0 million) in the previous year[5][9]. - The sales revenue of Lisangtuo® (Lazertinib) in China reached RMB 70.6 million (USD 10.1 million) for the year ending December 31, 2025[14]. - The commercialization of Lishengtuo® (Lisatochra) was initiated following its approval for treating adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in July 2025[6][7]. - The increase in sales and distribution expenses by 80.4% to RMB 353.6 million (USD 50.6 million) was attributed to the commercialization activities of Lishengtuo® and Nairike®[9][10]. - The number of hospitals and DTP pharmacies with access to Nairike® (Aurebacitinib) increased by 12.4% to 825 as of December 31, 2025, with the number of hospitals rising approximately 36.5% to 355[14]. Strategic Partnerships and Collaborations - The company has established collaborations with leading biotech and pharmaceutical companies, including AstraZeneca, Merck, and Pfizer, as well as research institutions like Dana-Farber Cancer Institute and Mayo Clinic[22]. - The company continues to collaborate closely with Takeda Pharmaceutical to implement the option agreement for Orelabrutinib, highlighting ongoing strategic partnerships[74]. - The company is strategically seeking partnerships to maximize the potential of its product portfolio and provide sustainable support for pipeline development[161]. Clinical Trials and Approvals - The FDA and EMA approved Lisangtuo® (Lazertinib) for the treatment of adult CLL/SLL patients who have received at least one prior systemic therapy including a BTK inhibitor[14]. - The global registration Phase III trial for Nairike® (Aurebacitinib) in first-line Ph+ ALL patients received FDA and EMA approval[17]. - The ongoing global Phase III clinical trial (GLORA) for Lishangtuo in combination with BTK inhibitors for previously treated CLL/SLL patients has received approvals from FDA, EMA, and CDE[35]. - The company is also conducting a global Phase III registration trial POLARIS-1 for Orebatin in first-line Ph+ ALL patients, with FDA and EMA approval[155]. Financial Position and Liquidity - The company’s cash and bank balances rose by 95.9% to RMB 2,470.1 million (USD 353.2 million) from RMB 1,261.2 million (USD 172.8 million) in the previous year, primarily due to cash inflows from the IPO and subsequent share placements[11]. - The company's equity increased to RMB 1,334,212 thousand in 2025, compared to RMB 274,162 thousand in 2024, showing significant growth in shareholder value[78]. - The current ratio improved to 1.8 for the year ending December 31, 2025, from 1.3 for the year ending December 31, 2024[130]. - The total liabilities as of December 31, 2025, amount to RMB 1,979.7 million, an increase from RMB 1,668.5 million in 2024, indicating a year-over-year growth of approximately 18.6%[139]. Corporate Governance and Compliance - The company has a comprehensive governance structure in place, ensuring compliance with corporate governance codes and maintaining a balance of power within the board[162]. - The company has established an audit committee consisting of two independent non-executive directors and one non-executive director[200]. - The company has not adopted any new accounting standards that would impact its financial reporting, maintaining consistency in its financial practices[80].
亚盛医药(06855) - 2025 - 年度业绩